Understanding the mechanism of lymph node metastasis, a poor prognostic sign for prostate cancer, and the further dissemination of the disease is important to develop novel treatment strategies. Recent studies have reported that C-C chemokine receptor 7 (CCR7), whose ligand is CCL21, is abundantly expressed in lymph node metastasis and promotes cancer progression. Tumor necrosis factor-a (TNF-a) is chronically produced at low levels within the tumor microenvironment. The aim of this study was to determine whether TNF-a promotes prostate cancer dissemination from metastatic lymph nodes through activation of the CCL21/CCR7 axis. First, human prostate cancer cells were determined to express both TNF-a and CCR7. Second, low concentrations of TNF-a were confirmed to induce CCR7 in prostate cancer cells through phosphorylation of ERK. Finally, CCL21 was found to promote the migration of prostate cancer cells through phosphorylation of the protein kinase p38. Our results suggest that TNFa leads to the induction of CCR7 expression and that the CCL21/CCR7 axis might increase the metastatic potential of prostate cancer cells in lymph node metastasis.
| INTRODUCTION
Prostate cancer is one of the most frequently diagnosed malignancies in men worldwide.
1 Approximately 70%-80% of patients with prostate cancer develop bone metastases, 2 and regional lymph node metastasis is observed in 5%-12% of patients with prostate cancer with clinically organ-confined cancer. 3 The detection of lymph node metastasis in prostate cancer, which remains incurable, indicates a poor prognosis for patients. [4] [5] [6] Therefore, understanding the mechanism of lymph node metastasis and the further dissemination of the disease is important to develop novel treatment strategies.
Tumor necrosis factor-a (TNF-a), which has pluripotent effects on tumorigenesis and tumor progression, is produced by cancer cells as well as the tumor microenvironment. 7, 8 Increased C-C chemokine receptor 7 (CCR7) expression in tumor cells has been reported to be significantly associated with lymph node metastasis in several cancer types. [9] [10] [11] Interestingly, CCR7 has been found to mediate TNF-ainduced lymphatic metastasis of gallbladder cancer. 12,13 C-C chemokine receptor 7 is a receptor for the chemokine CCL21 and is expressed in various immune cells that migrate to and within lymphoid tissues. Chemokine CCL21 is abundantly expressed on fibroblastic reticular cells in lymph node metastasis. 14 Although several chemokine receptors contribute to the increased migration ability of cancer cells in specific organs, [15] [16] [17] whether TNF-a and CCR7
deteriorate prostate cancer cells within the microenvironment of lymph node metastasis remains unclear.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
In the present study, we found that low TNF-a concentrations increase CCR7 expression through the phosphorylation of ERK in prostate cancer cells and that the CCL21/CCR7 axis promotes prostate cancer cell migration through phosphorylation of p38.
| MATERIALS AND METHODS

| Reagents and antibodies
Recombinant human TNF-a (210-TA) and CCL21 (366-6C) were purchased from R&D Systems (Minneapolis, MN, USA To investigate CCR7 upregulation in prostate cancer cells, cells were seeded in 6-well plates and allowed to reach 70%-80% confluence, followed by treatment with recombinant human TNF-a (10 ng/mL) for 6 hour in serum-free medium.
To evaluate the ERK signaling pathway in prostate cancer cells, cells were seeded in 6-well plates and allowed to reach 60%-70% confluence. The cells were synchronized by starvation in serum-free RPMI-1640 medium for 12 hour, followed by incubation with U0126
(10 lmol/L) in serum-free RPMI-1640 for 1 hour. Next, the cells were incubated with recombinant human TNF-a (10 ng/mL) for 20 minutes in serum-free medium. The following procedures were the same as above. 
| Reverse transcription-PCR
| Western blot analysis
| Immunocytochemistry
Prostate cancer cells were seeded at a concentration of 1.0 9 10 5 cells/well into 6-well plates and cultured until they reached 60%-70% confluence for immunocytochemistry. The cells were washed with PBS and fixed in 4% paraformaldehyde in PBS for 15 minutes at room temperature. After washing three times with ice-cold PBS, the cells were permeabilized with incubation in PBS containing 0.25% Triton X-100 for 15 minutes at room temperature.
The cells were washed three times with PBS and blocked with polybutylene succinate-co-butylene terephthalate containing 10% serum from the species of the secondary antibody for 30 minutes at room temperature. Next, the cells were incubated with the indicated primary antibodies overnight at 4°C, as described by the manufacturer.
Tumor necrosis factor-a was detected by incubating cells for 1 hour with an FITC-conjugated TNF-a antibody (1:1000). The cells were counterstained with 4',6-Diamidino-2-phenylindole dihydrochloride (Sigma-Aldrich, St. Louis, MO, USA), and images were captured using an Olympus FSX100 (Olympus, Tokyo, Japan).
| Cell migration assay
The cell migration assay was carried out using Transwell inserts placed in 24-well plates, which had a pore size of 8.0 lm (Greiner Bio-One, Monroe, NC, USA). PC-3 and DU145 prostate cancer cell lines were grown to 80% confluence in growth medium, followed by synchronization by starvation in serum-free RPMI-1640 containing 0.5% BSA for 16 hour in a humidified incubator containing 5% CO 2 at 37°C. To determine migration in LNCaP cells, the cells were seeded in 6-well plates and allowed to reach 70%-80% confluence, Statistical analysis was undertaken using Student's t-test. A P-value <.05 was considered statistically significant. (50 ng/mL) for 24 or 48 hour. Phase-contrast images were captured at 0 and 24 hour with a 109 objective using an Olympus FSX100 microscope. Migration activity was expressed using the transferred distance method determined using ImageJ software (NIH, Bethesda, MD, USA). Three separate visual fields were measured in each experiment. Statistical analysis was carried out using Student's t-test.
A P-value <.05 was considered statistically significant.
| Proliferation assay
PC-3 cells were seeded at a density of 2.0 9 10 3 cells/well in 96-well plates in media containing RPMI-1640 and 5% FBS. Twelve hours after seeding, the medium was changed to serum-free RPMI-1640 with or without TNF-a at different concentrations. Cell growth was determined at 0, 24, 48, and 72 hour using the WST-1 assay (Takara Bio). Briefly, WST-1 (10 lL/well) was added to each well and incubated for 105 minutes at 37°C. Absorbance was measured at 595 nm and corrected at 450 nm on a microplate reader.
| Statistical analysis
Student's t-test was used to determine the statistical significance of differences in the results of the wound healing assay between two groups. For multiple comparisons, one-way ANOVA, followed by Bonferroni's test, was used to determine the statistical significance of differences in the proliferation and Transwell migration assay results.
P < .05 was considered statistically significant.
| RESULTS
| Tumor necrosis factor-a and CCR7 expression and TNF-a effect in prostate cancer cells
We first determined TNF-a and CCR7 mRNA levels in PC-3, DU145, LNCaP, and LNCaP-SF prostate cancer cell lines using RT-PCR, which indicated that TNF-a and CCR7 mRNA are expressed at detectable levels in all cell lines ( Figure 1A ). Additionally, Western blotting and immunocytochemistry revealed that TNF-a and CCR7
are also expressed at the protein level in all cell lines ( Figure 1B,C) .
Following exogenous stimulation with 10 ng/mL TNF-a, TNF-a protein levels in prostate cancer cells increased gradually for up to 6 hour in an autocrine fashion ( Figure 1D ). PC-3 cells were also treated with TNF-a at different concentrations for up to 3 days to assess whether TNF-a induces prostate cancer cell proliferation.
Although higher TNF-a concentrations (100 and 300 ng/mL) significantly inhibited cell proliferation ( Figure 1E Figure 3B ). These results indicate that TNF-a upregulates CCR7 through the ERK signaling pathway.
| C-C chemokine ligand 21/CCR7 signaling promotes prostate cancer cell migration through activation of p38
The interaction between CCR7 and mitogen-activated protein kinase in the lymphatic dissemination of breast cancer has been reported. 18 Furthermore, we previously showed that chemokines increase cell migration and invasion ability through AKT activation. 19, 20 Therefore, p38, ERK, and AKT were investigated as potential downstream effectors of CCL21/CCR7 signaling during prostate cancer cell migration. As shown in Figure 4 (A), despite a gradual increase in p38 following stimulation with 30 ng/mL CCL21, we failed to detect phosphorylation of ERK or AKT ( Figure 4B,C) .
F I G U R E 1 Low-dose tumor necrosis factor-a (TNF-a) induces C-C chemokine receptor 7 (CCR7) expression in prostate cancer cells. A,B, Total RNA and protein were extracted from prostate cancer cells, and their mRNA and protein levels were analyzed using RT-PCR A and Western blotting B. C, Prostate cancer cells (1.0 9 10 5 cells/well) were seeded into 6-well plates and cultured until they reached 60%-70%
confluence. The cells were incubated with a primary anti-TNF-a antibody, followed by incubation with a secondary antibody conjugated with FITC (green). Cells were counterstained with DAPI (blue). D, Changes in TNF-a protein levels in prostate cancer cells after stimulation with exogenous TNF-a (10 ng/mL) were determined by Western blotting. E, PC-3 cell proliferation was determined with the WST-1 assay using a range of TNF-a concentrations. Although high TNF-a concentrations (100 and 300 ng/mL, compared with 0 ng/mL, P < .01) significantly inhibited cell proliferation at 72 hour (upper panel), low concentrations did not lead to inhibition of cell proliferation (lower panel). Data are presented as mean AE SD. F, Prostate cancer cells were treated with TNF-a at different concentrations for 6 hour, and Western blot analysis was used to detect CCR7
3.5 | Blockade of p38 inhibits CCL21/CCR7
signaling-induced migration of prostate cancer cells
To determine whether p38 is responsible for the increase in the migration ability of prostate cancer cells, the p38 inhibitor SB203580 was used in the migration assay for prostate cancer cells. In the wound-healing assay, SB203580 treatment led to a significant suppression of CCL21/CCR7-mediated PC-3 and DU145 cell migration ( Figure 5 ). These results clearly indicate that p38 is a downstream target of CCL21/CCR7 signaling and a key factor in the acceleration of prostate cancer cell migration. Figure 2B ). C-C chemokine ligand 21 F I G U R E 4 C-C chemokine ligand 21 (CCL21)/C-C chemokine receptor 7 (CCR7) signaling promotes prostate cancer cell migration through the activation of p38. Phosphorylation (p-) of p38 A, ERK B, and AKT C in prostate cancer cells at the indicated times after CCL21 stimulation was assessed using Western blotting F I G U R E 5 Blockade of p38 inhibits C-C chemokine ligand 21 (CCL21)/C-C chemokine receptor 7 (CCR7) signaling-induced prostate cancer cell migration. The effect of UB203580 on CCL21/CCR7 signaling-induced migration in PC-3 A, and DU145 B, cells was assessed using the wound-healing assay. Cells were pretreated with 10 lmol/L SB203580 for 1 hour, followed by incubation with 30 ng/mL CCL2 for 24 hour. Data are presented as means AE SD. All experiments were performed in triplicate. *P < .05 certainly activates p38; however, TNF-a is needed to sufficiently increase the CCR7 expression level to induce LNCaP cell migration.
These findings support our hypothesis that TNF-a induces the migration of prostate cancer cells in the microenvironment of lymph node metastasis through the TNF-a/ERK/CCR7/p38 signaling pathway ( Figure 6 ). In combination with androgen-deprivation therapy, the CCL21/CCR7 axis might be a superior target compared with single androgen/androgen receptor signaling-targeted therapy for the treatment of patients with prostate cancer and lymph node metastasis.
Furthermore, the CCL21/CCR7 axis might be a novel biomarker for prostate cancer. The limitations of using prostate-specific antigen alone as a biomarker for prostate cancer have been extensively reported, and the need for more specific and effective biomarkers is evident. 21, 22 Previously, we reported that the serum CCL2 level in patients with prostate cancer is clearly predictive of the time interval for the tumor to become castration-resistant as well as the overall and prostate cancer-specific survival rates. 23 C-C chemokine ligand 2 is a secreted protein and can be measured easily in a patient's serum; CCL21 is also a secreted chemokine and is abundantly expressed on fibroblastic reticular cells in lymph node metastasis.
However, additional clinical evidence is necessary to establish the superiority of the CCL21/CCR7 axis over the CCL2/CCR2 axis as a prostate cancer biomarker.
In conclusion, our data suggest that TNF-a acts as a regulator of increased tumor cell migration through the upregulation of CCR7.
Targeting TNF-a and ultimately the CCL21/CCR7 axis is a novel therapeutic strategy for patients with prostate cancer.
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